Skip to content

Capsulomics

6 viewers · 30d

Total raised

$2.4M

1 filing since 2019 · latest Other filed

Cumulative raised
LAST ROUND
Other · $2.4M
ROUNDS
1
INVESTORS
10
FOUNDED
N/A
HQ
Halethorpe, MD
SECTOR
Healthcare
EMPLOYEES
N/A
30D VIEWERS
6

AI overview

Updated

Capsulomics, Inc., now known as Previse, is a pioneering medical diagnostics company dedicated to the early detection and prevention of esophageal cancer. The firm leverages cutting-edge molecular testing to empower gastroenterologists with critical insights into patient risk profiles for more informed treatment options.

What sets it apart

Capsulomics stands out by offering Esopredict, a unique molecular test developed from research at Johns Hopkins University, focusing specifically on personalized risk assessment for Barrett's esophagus patients.

Funding history

1 round
OtherDec 17, 2019
Form D/A
+$2.4M$2.4M total

Latest SEC filings

via EDGAR · CIK 0001800623
Form D/A · Dec 17, 2019View on EDGAR

Products

1 tracked

Esopredict

Molecular Diagnostics

Esopredict is a cutting-edge molecular diagnostic test that assesses the risk of Barrett's esophagus patients progressing to high-grade dysplasia or esophageal adenocarcinoma. By analyzing DNA methylation biomarkers within esophageal tissue samples, it provides a personalized risk assessment for individuals already diagnosed with Barrett's esophagus.

  • Analysis of DNA methylation biomarkers
  • Personalized risk assessment for Barrett's esophagus
  • Supports targeted monitoring and treatment plans

Links

WebsiteSEC EDGAR filings